anti-4.1BB antibody

Anti-4-1BB antibodies (also known as anti-CD137 antibodies) are a class of agonistic monoclonal antibodies designed to stimulate the 4-1BB receptor, a member of the tumor necrosis factor receptor (TNFR) superfamily. 4-1BB is primarily expressed on activated T cells and natural killer (NK) cells, where it functions as a potent costimulatory molecule. Upon binding, these antibodies trigger signaling pathways that enhance T-cell proliferation, survival, and effector functions, such as cytokine production and cytolytic activity. This mechanism is intended to augment the anti-tumor immune response. Clinical development has seen two primary generations: first-generation agonists like urelumab (IgG4) and utomilumab (IgG2), which faced challenges regarding liver toxicity and efficacy, and next-generation molecules including bispecific antibodies (e.g., 4-1BB x PD-L1) and localized agonists designed to improve the therapeutic window.

Other names

anti-4-1BB antibodyanti4-1BB antibodyanti 4-1BB antibodyanti-CD137 antibodyanti-CD-137 antibodyanti-CD 137 antibody4-1BB agonist antibodyCD137 agonist antibodyCD-137 agonist antibodyCD 137 agonist antibodyanti-4-1BBanti4-1BBanti 4-1BB